Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications
- 1Hunan University of Chinese Medicine Changsha Hunan China
- 2Hinye Pharmaceutical Co. Ltd. Changsha Hunan China
- 3The Second Affiliated Hospital of Hunan University of Chinese Medicine Changsha Hunan China
Abstract
Early diagnosis remains challenging, recurrence rates remain high, and platinum resistance frequently develops in ovarian cancer (OC), collectively representing major barriers to long‐term patient survival. DNA methylation (DNAm), as a relatively stable yet dynamically modifiable epigenetic signature, can capture alterations in tumor states and evolutionary trajectories associated with therapeutic pressure. Meanwhile, the circadian rhythm system regulates multiple cancer‐related processes, including DNA damage repair, cell‐cycle progression, metabolic adaptation, and immune microenvironment remodeling, thereby influencing OC development and treatment responses. Accumulating evidence suggests the existence of a bidirectional interplay between DNAm landscapes and the circadian clock network in OC. This review summarizes the emerging mechanisms underlying the crosstalk between DNAm and circadian reprogramming in OC, and further discusses their potential applications in early detection, prognostic stratification, dynamic monitoring of platinum resistance, and chronotherapy‐based therapeutic strategies. Although current findings highlight the promising translational potential of the DNAm–circadian axis, its clinical implementation remains constrained by tumor heterogeneity, variations in sampling time points, cellular composition complexity, and insufficient validation across experimental models and clinical cohorts. Future integration of time‐resolved sampling approaches, liquid biopsy platforms, single‐cell and spatial epigenomic technologies, as well as prospective clinical trials evaluating circadian‐guided interventions, may further define the translational boundaries and clinical utility of DNAm–circadian coupling in precision diagnosis and treatment of OC.
Related
- HMGB1 in Amyloid-Beta Pathology: Mechanistic Insights and Therapeutic Implications for Alzheimer’s Disease
- Salidroside Regulates Energy Metabolism Reprogramming to Suppress Tumor Proliferation: Mechanisms and Therapeutic Implications
- Crosstalk between gut microbiota-associated metabolites and adaptive immunity in cholecystitis: a conceptual mechanistic framework and potential therapeutic implications
- Histone Acetylation in Bone Remodeling: Metabolic Regulation, Lineage-Specific Chromatin Programs, and Therapeutic Implications
- Characterization of DNA methylation in PBMCs and donor-matched iPSCs shows age-related methylation is reset during stem cell reprogramming
BibTeX
@article{xing2026crossregulation,
title = {{Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications}},
author = {Min Xing and Chang Zhou and Yi Tang and Shuhui Xu and Shasha Zhou and Weiai Liu and Huiping Liu},
journal = {International Journal of Cancer},
year = {2026},
month = aug,
doi = {10.1002/ijc.70704},
url = {https://doi.org/10.1002/ijc.70704},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications
AU - Min Xing
AU - Chang Zhou
AU - Yi Tang
AU - Shuhui Xu
AU - Shasha Zhou
AU - Weiai Liu
AU - Huiping Liu
PY - 2026
DA - 2026/08/19
JO - International Journal of Cancer
DO - 10.1002/ijc.70704
UR - https://doi.org/10.1002/ijc.70704
AB - Early diagnosis remains challenging, recurrence rates remain high, and platinum resistance frequently develops in ovarian cancer (OC), collectively representing major barriers to long‐term patient survival. DNA methylation (DNAm), as a relatively stable yet dynamically modifiable epigenetic signature, can capture alterations in tumor states and evolutionary trajectories associated with therapeutic pressure. Meanwhile, the circadian rhythm system regulates multiple cancer‐related processes, including DNA damage repair, cell‐cycle progression, metabolic adaptation, and immune microenvironment remodeling, thereby influencing OC development and treatment responses. Accumulating evidence suggests the existence of a bidirectional interplay between DNAm landscapes and the circadian clock network in OC. This review summarizes the emerging mechanisms underlying the crosstalk between DNAm and circadian reprogramming in OC, and further discusses their potential applications in early detection, prognostic stratification, dynamic monitoring of platinum resistance, and chronotherapy‐based therapeutic strategies. Although current findings highlight the promising translational potential of the DNAm–circadian axis, its clinical implementation remains constrained by tumor heterogeneity, variations in sampling time points, cellular composition complexity, and insufficient validation across experimental models and clinical cohorts. Future integration of time‐resolved sampling approaches, liquid biopsy platforms, single‐cell and spatial epigenomic technologies, as well as prospective clinical trials evaluating circadian‐guided interventions, may further define the translational boundaries and clinical utility of DNAm–circadian coupling in precision diagnosis and treatment of OC.
SN - 0020-7136
SN - 1097-0215
ER -